Events & Presentations
Upcoming Events
Dec 11, 2022
at 6:00 PM - 8:00 PM CST
An abstract (Abstract# 3334) titled, "A Phase1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies," will be presented as a trial-in-progress presentation.
Dec 12, 2022
at 6:00 PM - 8:00 PM CST
An abstract (Abstract# 4633) titled, "Phase 1/1b Safety Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes," will be presented as a poster presentation.
Past Events
Nov 09, 2022 at 4:30 PM EST
Precigen quarterly financial results and general business update. The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and providing the participant access code 3010378. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.
Nov 08, 2022
Helen Sabzevari, PhD, Precigen President and CEO, to participate in Science of Business Fireside Chat.
Sep 07, 2022 at 11:35 AM EDT
Helen Sabzevari, PhD, President and CEO, participated in a fireside chat at the 2022 Wells Fargo Healthcare Conference in Boston, Massachusetts.
Aug 08, 2022 at 4:30 PM EDT
Precigen quarterly and half year financial results and general business update.
Jun 30, 2022 at 1:00 PM EDT
Helen Sabzevari, President and CEO of Precigen, participated in a virtual panel discussion titled, “Targeted T Cell Therapies, Including Autologous CAR T, TCR and More”.
May 24, 2022 at 7:00 AM EDT
Helen Sabzevari, President and CEO of Precigen, participated in a virtual fireside chat.
May 09, 2022 at 4:05 PM EDT
Precigen first quarter 2022 financial results.
Apr 12, 2022
at 9:00 AM - 12:30 PM CDT
An abstract titled, "Incorporation of intrinsic checkpoint blockade enhances functionality of multigenic autologous UltraCAR-T® cells manufactured using non-viral gene delivery and rapid manufacturing process," was presented as a poster presentation.
Apr 12 - Apr 13, 2022
Precigen participated in the event held at the PGA National Resort in Palm Beach Gardens, Florida.
Mar 01, 2022 at 8:00 AM EST
Precigen quarterly and full year financial results.
Jan 12, 2022 at 3:45 PM EST
Helen Sabzevari, President and CEO of Precigen, presented a corporate and clinical overview.
Jan 11, 2022 at 12:00 PM EST
Dr. Sabzevari, PhD, President and CEO of Precigen, participated in a panel discussion titled, The Emerging Cell & Gene Therapy Landscape - From Hope to Reality, hosted by Scott Gottlieb, MD.
Dec 13, 2021 at 5:00 PM EST
An abstract for the PRGN-3006 Phase 1 trial (Abstract# 825) titled, "Phase 1/1b Safety Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes," was selected for oral presentation and was presented by David Sallman, MD, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffitt Cancer Center & Research Institute and a lead investigator for the PRGN-3006 clinical trial.
Dec 11, 2021
at 5:30 PM - 7:30 PM EST
An abstract highlighting PRGN-3007 preclinical data (Abstract# 1694) titled, “Preclinical evaluation of PRGN-3007, a non-viral, multigenic, autologous ROR1 UltraCAR-T® cell therapy with novel mechanism of intrinsic PD-1 blockade for treatment of hematological and solid cancers,” was presented as a poster presentation.
Nov 17, 2021 at 10:40 AM EST
Helen Sabzevari, PhD, President and CEO, presented at the Stifel 2021 Virtual Healthcare Conference.
Nov 12, 2021
A trial-in-progress update on the PRGN-2009 study titled, “Initial safety results and immune responses induced by a novel human papillomavirus (HPV)-specific gorilla adenovirus immunotherapy vaccine, PRGN-2009, in patients with advanced HPV-associated cancers,” was presented as a poster presentation (#483) by Charalampos S. Floudas, MD, DMSc, MS, Assistant Research Physician, Genitourinary Malignancies Branch at the Center for Cancer Research at the National Cancer Institute (NCI).
Nov 04, 2021 at 11:00 AM EDT
Precigen's 2021 R&D Day featured clinical pipeline and data updates from clinical trial investigators and Precigen executives.
Oct 13, 2021 at 4:45 PM PDT
Helen Sabzevari, PhD, President and CEO of Precigen, presented a company overview.
Oct 01, 2021 at 12:00 PM CEST
The abstract entitled, "AG019 ActoBiotics as monotherapy or in association with teplizumab in recent-onset type 1 diabetes was safe and demonstrated encouraging metabolic and immunological effects" was presented by Chantal Mathieu, MD, PhD, Professor of Medicine at the Katholieke Universiteit Leuven, Belgium.
Sep 13, 2021 at 7:00 AM EDT
Helen Sabzevari, PhD, President and CEO, presented at the H.C. Wainwright Annual Global Investment Conference.
Sep 09, 2021 at 8:40 AM EDT
Helen Sabzevari, PhD, President and CEO, participated in a virtual fireside chat at the 2021 Wells Fargo Virtual Healthcare Conference.
Aug 09, 2021 at 4:05 PM EDT
Precigen quarterly and half year financial results and general business update.
Jun 17, 2021 at 11:00 AM EDT
Helen Sabzevari, PhD, President and CEO of Precigen, participated in a virtual fireside chat at the annual JMP Securities Life Sciences Conference.
Jun 10, 2021
at 5:05 PM - 5:20 PM EDT
Oral presentation of the AG019 abstract "Lactococcus lactis producing Proinsulin and IL-10 therapy increases Antigen Specific Regulatory T-cells in Monotherapy and in Combination with an anti-CD3 Monoclonal Antibody (Teplizumab) in newly diagnosed T1D patients." The abstract was presented by Kevan Herold, MD, CNH Long Professor of Immunobiology and of Medicine (Endocrinology) at the Yale School of Medicine.
Jun 04, 2021 at 9:00 AM EDT
Trial-in-progress poster presentation of the PRGN-2009 abstract "First-in-human Phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC)." The poster presentation will be presented by Charalampos S. Floudas, MD, DMSc, MS, Assistant Research Physician, Genitourinary Malignancies Branch at the Center for Cancer Research at the National Cancer Institute (NCI). Presented in Poster Sessions: Head and Neck Cancer.
May 21, 2021 at 12:45 PM EDT
Oral presentation of the abstract "Adenovirus vectors for human therapeutics." The abstract was presented by Douglas E. Brough, PhD, Head of Research, Precigen. Presented in Session 12: Gene Delivery.
View presentation 5.3 MB
May 10, 2021 at 4:30 PM EDT
Precigen first quarter 2021 financial results and general business update.
Mar 09, 2021 at 7:00 AM EST
Helen Sabzevari, PhD, President and CEO, presented at the H.C. Wainwright Virtual Global Life Sciences Conference.
Mar 01, 2021 at 4:30 PM EST
Precigen quarterly and full year financial results and general business update.